Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

450763

registered interest
date	04/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the written statement of 5 January 2016, HCWS447, what the value is of the payment that will be made to his Department by the pharmaceutical industry in 2016 referred to in that statement.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	25939
answer	answer is ministerial correction date of answer 09/02/2016 answer text <p>The Department publishes the estimated United Kingdom and England Income from the Pharmaceutical Price Regulation Scheme (PPRS) payments on the GOV.UK website.</p><p> </p><p>This information is available to view at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/487575/payment_percentage_2016.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/487575/payment_percentage_2016.pdf</a></p><p> </p><p>Estimated UK and England income from PPRS payments</p><p> </p><table><tbody><tr><td><p>£ million</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td></tr><tr><td><p>UK</p></td><td><p>800</p></td><td><p>647</p></td></tr><tr><td><p>England</p></td><td><p>640</p></td><td><p>518</p></td></tr></tbody></table><p> </p><p> </p><p>Individual PPRS members make quarterly PPRS Payments to the Department in arrears. Each payment, which is based on a company’s quarterly sales report, is made one month after the end of each quarter of the calendar year.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 25938 question first answered 09/02/2016 14:24:39 answering member 4020 label Biography information for George Freeman
tabling member	4418 label Biography information for Justin Madders

450773

registered interest
date	04/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the written statement of 5 January 2016, HCWS447, in what month of 2016 his Department expects to receive the advance payment from the pharmaceutical industry referred to in that statement.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	25938
answer	answer is ministerial correction date of answer 09/02/2016 answer text <p>The Department publishes the estimated United Kingdom and England Income from the Pharmaceutical Price Regulation Scheme (PPRS) payments on the GOV.UK website.</p><p> </p><p>This information is available to view at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/487575/payment_percentage_2016.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/487575/payment_percentage_2016.pdf</a></p><p> </p><p>Estimated UK and England income from PPRS payments</p><p> </p><table><tbody><tr><td><p>£ million</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td></tr><tr><td><p>UK</p></td><td><p>800</p></td><td><p>647</p></td></tr><tr><td><p>England</p></td><td><p>640</p></td><td><p>518</p></td></tr></tbody></table><p> </p><p> </p><p>Individual PPRS members make quarterly PPRS Payments to the Department in arrears. Each payment, which is based on a company’s quarterly sales report, is made one month after the end of each quarter of the calendar year.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 25939 question first answered 09/02/2016 14:24:39 answering member 4020 label Biography information for George Freeman
tabling member	4418 label Biography information for Justin Madders

437917

registered interest
date	14/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, which companies have left the voluntary pharmaceutical price regulation scheme in each month since January 2014 to date; and if he will make a statement.
tabling member constituency	Aberavon
tabling member printed	Stephen Kinnock
uin	19894
answer	answer is ministerial correction date of answer 17/12/2015 answer text <br /><p>Five companies have left the Pharmaceutical Price Regulation Scheme since January 2014 as follows:</p><br /><p>- Derma November 2014;</p><p>- Genus (Thornton &amp; Ross) November 2014;</p><p>- Vifor May 2015;</p><p>- Baxter October 2015; and</p><p>- Martindale October 2015</p><br /><p>The Department estimates the financial effect to be a loss of around £10 million in 2015/16.</p><br /><p>The Department’s consultation on options to amend the statutory scheme to control prices of branded health service medicines closed on 4 December 2015. The consultation was accompanied by an Impact Assessment which can be accessed:</p><br /><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf</a></p><br /><p>The Department’s analysis in the Impact Assessment concludes that the options would reduce National Health Service spending on drugs without affecting the use of those drugs in the NHS. The consultation sought views, comments and evidence on the potential impacts and operation of the options to revise thestatutory branded prices scheme. The Department is considering the responses received and will respond to the consultation in early 2016.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 19895 19897 question first answered 17/12/2015 16:19:37 answering member 4020 label Biography information for George Freeman
tabling member	4359 label Biography information for Stephen Kinnock

437918

registered interest
date	14/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the financial effect of companies leaving the voluntary pharmaceutical price regulation scheme in the 2015-16 financial year.
tabling member constituency	Aberavon
tabling member printed	Stephen Kinnock
uin	19895
answer	answer is ministerial correction date of answer 17/12/2015 answer text <br /><p>Five companies have left the Pharmaceutical Price Regulation Scheme since January 2014 as follows:</p><br /><p>- Derma November 2014;</p><p>- Genus (Thornton &amp; Ross) November 2014;</p><p>- Vifor May 2015;</p><p>- Baxter October 2015; and</p><p>- Martindale October 2015</p><br /><p>The Department estimates the financial effect to be a loss of around £10 million in 2015/16.</p><br /><p>The Department’s consultation on options to amend the statutory scheme to control prices of branded health service medicines closed on 4 December 2015. The consultation was accompanied by an Impact Assessment which can be accessed:</p><br /><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf</a></p><br /><p>The Department’s analysis in the Impact Assessment concludes that the options would reduce National Health Service spending on drugs without affecting the use of those drugs in the NHS. The consultation sought views, comments and evidence on the potential impacts and operation of the options to revise thestatutory branded prices scheme. The Department is considering the responses received and will respond to the consultation in early 2016.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 19894 19897 question first answered 17/12/2015 16:19:37 answering member 4020 label Biography information for George Freeman
tabling member	4359 label Biography information for Stephen Kinnock

425134

registered interest
date	30/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to page 21 of his Department's Pharmaceutical Price Regulation Scheme, published in December 2013, when he plans to publish information on the comparative use of medicines in the NHS referred to in that document; by which channels he plans that information to be published; what plans he has to communicate that information proactively through the NHS; whether he intends to communicate that information to patients; and if he will make a statement.
tabling member constituency	Bromley and Chislehurst
tabling member printed	Robert Neill
uin	14247
answer	answer is ministerial correction date of answer 09/11/2015 answer text <p>The Life Science Competitiveness Indicators were published for the first time in March 2015 and are available to all. The publication can be found here:</p><br /><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418305/BIS-15-249-life-science-competitiveness-indicators.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418305/BIS-15-249-life-science-competitiveness-indicators.pdf</a></p><br /><p>The Competitiveness Indicators were the product of extensive collaboration with colleagues from across the life science sector, including from industry. In developing the Indicators, issues such as the availability and reliability of data, the potential for international comparisons and relevance to United Kingdom competitiveness in life sciences were considered in establishing which measures to include.</p><br /><p>We plan to publish the 2016 Life Science Competitiveness Indicators in March 2016. Our intention is to maintain as much consistency in content as possible, in order to facilitate analysis of progress over time, which can in turn inform policy development.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 14248 question first answered 09/11/2015 15:56:31 answering member 4020 label Biography information for George Freeman
tabling member	1601 label Biography information for Sir Robert Neill

425135

registered interest
date	30/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to page 21 of his Department's Pharmaceutical Price Regulation Scheme, published in December 2013, when he plans to refresh the annual indicators arising from the Pharmaceutical Industry Competitiveness Taskforce referred to in that document; if he will make it his policy to include (a) medicines expenditure per head of population, (b) market sales as a percentage of GDP and (c) average pricing and reimbursement delays in the set of those indicators; and if he will make a statement.
tabling member constituency	Bromley and Chislehurst
tabling member printed	Robert Neill
uin	14248
answer	answer is ministerial correction date of answer 09/11/2015 answer text <p>The Life Science Competitiveness Indicators were published for the first time in March 2015 and are available to all. The publication can be found here:</p><br /><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418305/BIS-15-249-life-science-competitiveness-indicators.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418305/BIS-15-249-life-science-competitiveness-indicators.pdf</a></p><br /><p>The Competitiveness Indicators were the product of extensive collaboration with colleagues from across the life science sector, including from industry. In developing the Indicators, issues such as the availability and reliability of data, the potential for international comparisons and relevance to United Kingdom competitiveness in life sciences were considered in establishing which measures to include.</p><br /><p>We plan to publish the 2016 Life Science Competitiveness Indicators in March 2016. Our intention is to maintain as much consistency in content as possible, in order to facilitate analysis of progress over time, which can in turn inform policy development.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 14247 question first answered 09/11/2015 15:56:31 answering member 4020 label Biography information for George Freeman
tabling member	1601 label Biography information for Sir Robert Neill

425136

registered interest
date	30/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what payments have been made to the devolved administrations under the 2014 Pharmaceutical Price Regulation Scheme to date; on which date each such payment was made; what methodology is used to calculate the level of such payments; and if he will make a statement.
tabling member constituency	Bromley and Chislehurst
tabling member printed	Robert Neill
uin	14249
answer	answer is ministerial correction date of answer 09/11/2015 answer text <p>The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way.</p><p>The PPRS payments that companies make under the scheme in respect of the UK are allocated to each of the four countries on an agreed basis each year. Apportionment is not covered by the terms of the PPRS. However, the four countries agreed the current method for apportioning income received under the 2014 PPRS which is based on primary care data for spend on licensed branded medicines, as the most consistent data set available across the UK. Income is apportioned using prescribing data for the same period as the income relates.</p><br /><p>The attached table includes the quarterly PPRS income paid to Scotland, Northern Ireland and Wales from Q1 2014 to Q2 2015. It should be noted that as well as PPRS payments this income also includes historic cash payments made by companies that were members of the 2009 PPRS.</p><br /><p>As requested, the following table contains information regarding the dates PPRS payments were made to the devolved administrations:</p><br /><table><tbody><tr><td><p><br></p></td><td><p>PPRS Payment</p></td><td><p>Historic Cash Payment</p></td></tr><tr><td><p>2014 Q1</p></td><td><p>21 August 2014</p></td><td><p>10 October 2014</p></td></tr><tr><td><p>2014 Q2 and Q3</p></td><td><p>20 February 2015</p></td><td><p>20 February 2015</p></td></tr><tr><td><p>2014 Q4</p></td><td><p>8 April 2015</p></td><td><p>8 April 2015</p></td></tr><tr><td><p>2015 Q1</p></td><td><p>3 July 2015</p></td><td><p>24 July 2015</p></td></tr><tr><td><p>2015 Q2</p></td><td><p>13 October 2015</p></td><td><p>16 October 2015</p></td></tr></tbody></table><br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/11/2015 16:02:48 answering member 4020 label Biography information for George Freeman attachment 1 file name PPRS payments to Scotland, Northern Ireland and Wales 2014-15.docx title PPRS paid to Scotland, NI & Wales Q1 2014-Q2 2015
tabling member	1601 label Biography information for Sir Robert Neill

425137

registered interest
date	30/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to page 21 of the Pharmaceutical Price Regulations Scheme, what steps he is taking to encourage academic health science networks to translate research into practice.
tabling member constituency	Bromley and Chislehurst
tabling member printed	Robert Neill
uin	14250
answer	answer is ministerial correction date of answer 09/11/2015 answer text <p>Academic Health Science Networks (AHSNs) have been set up to support local health economies to improve health outcomes in their communities, and maximise the National Health Service’s contribution to economic growth by enabling change through collaboration, and the spread of innovation and best practice. To do this, they bring together local NHS partners, academia and industry by acting as catalysts, brokers, coordinators, sponsors and knowledge-sharers.</p><br /><p>Speeding up adoption of innovation into practice to improve clinical outcomes and patient experience has been one of the four core contractual objectives for AHSN since their establishment in 2013. As well as directly supporting partners to diffuse specific innovations and best practice, AHSNs also work to create an infrastructure and environment that enables the development, identification and adoption of innovation. This work encompasses the establishment of partnerships and networking opportunities, as well as investment in infrastructure.</p><br /><p>AHSNs are supporting over 150 active programmes and projects across a range of clinical and cross-cutting themes. These have been selected in response to the priorities of their local populations and health economies. In addition to their individual programmes, AHSNs also work collectively to support national priorities which include a Medicine’s Optimisation programme. AHSNs are working with NHS England and the <em>Association of the British Pharmaceutical Industry </em>among others to promote best practice that ensures patients, the public and society more broadly get the best outcomes from medicines. This includes programmes to encourage access to innovative medicines and to ensure safer use of medicines.</p><br /><p>AHSNs have taken a range of approaches in delivering their objectives. Case studies and exemplars of some their work can be found in the resources section of the AHSNs Network website: <a href="http://www.ahsnnetwork.com/" target="_blank">www.ahsnnetwork.com</a></p><br /> <br /><p><strong></strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/11/2015 16:04:41 answering member 4020 label Biography information for George Freeman
tabling member	1601 label Biography information for Sir Robert Neill

423977

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what payments were made to the devolved administrations under the terms of the 2014 Pharmaceutical Price Regulation Scheme in each quarter of (a) 2014-15 and (b) 2015-16 to date.
tabling member constituency	Chesham and Amersham
tabling member printed	Mrs Cheryl Gillan
uin	13351
answer	answer is ministerial correction date of answer 02/11/2015 answer text <p>The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way. The PPRS payments that companies make under the scheme in respect of the UK are allocated to each of the four countries on an agreed basis each year.</p><br /><p>Apportionment is not covered by the terms of the PPRS. However, the four countries agreed the current method for apportioning payments which is based on primary care spend for licensed branded medicines, as the most consistent data set available across the UK. Income is apportioned using prescribing data for the same period as the income relates. The Health Departments explored with industry whether an accurate four country split of PPRS sales data could be obtained to inform the apportionment, but not all companies are able to provide this data.</p><br /><p>The attached table includes the total quarterly PPRS income paid to Scotland, Northern Ireland and Wales from Q1 2014 to Q2 2015. Note that as well as PPRS payments this income also includes historic cash payments made by companies that were members of the 2009 PPRS.</p><br /><p>It should be noted that companies are currently submitting audited reports for 2014 which is likely to lead to some adjustments to the PPRS income already paid.</p><br /><p>The Department routinely publishes PPRS aggregate net sales and payment information quarterly at:</p><br /><p><a href="https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information" target="_blank">PPRS: quarterly net sales and payment information - Publications - GOV.UK</a></p><br /><p>The Department published estimates of the levels of PPRS payments expected in 2014/15 and 2015/16 when the payment percentage for 2015 was published in December 2014 at: <a href="https://www.gov.uk/government/publications/pprs-payment-percentage" target="_blank">https://www.gov.uk/government/publications/pprs-payment-percentage</a></p><br /><p>The Department intends to publish updated estimates for 2014/15, 2015/16 and 2016/17 in December 2015 when the payment percentage for 2016 is announced. The Department is not able to provide estimates for later years of the scheme as they would be very misleading due to the uncertainty involved.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13352 question first answered 02/11/2015 10:42:12 answering member 4020 label Biography information for George Freeman attachment 1 file name Total quarterly PPRS income- Scotland, N Ireland & Wales Q1 2014-Q2 2015.docx title Quarterly PPRS income- Scotland, N Ireland, Wales
tabling member	18 label Biography information for Dame Cheryl Gillan

423978

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much his Department has received each quarter in rebate payments under the Pharmaceutical Price Regulation Scheme; and what estimate his Department has made of receipts for the remainder of that scheme.
tabling member constituency	Chesham and Amersham
tabling member printed	Mrs Cheryl Gillan
uin	13352
answer	answer is ministerial correction date of answer 02/11/2015 answer text <p>The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way. The PPRS payments that companies make under the scheme in respect of the UK are allocated to each of the four countries on an agreed basis each year.</p><br /><p>Apportionment is not covered by the terms of the PPRS. However, the four countries agreed the current method for apportioning payments which is based on primary care spend for licensed branded medicines, as the most consistent data set available across the UK. Income is apportioned using prescribing data for the same period as the income relates. The Health Departments explored with industry whether an accurate four country split of PPRS sales data could be obtained to inform the apportionment, but not all companies are able to provide this data.</p><br /><p>The attached table includes the total quarterly PPRS income paid to Scotland, Northern Ireland and Wales from Q1 2014 to Q2 2015. Note that as well as PPRS payments this income also includes historic cash payments made by companies that were members of the 2009 PPRS.</p><br /><p>It should be noted that companies are currently submitting audited reports for 2014 which is likely to lead to some adjustments to the PPRS income already paid.</p><br /><p>The Department routinely publishes PPRS aggregate net sales and payment information quarterly at:</p><br /><p><a href="https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information" target="_blank">PPRS: quarterly net sales and payment information - Publications - GOV.UK</a></p><br /><p>The Department published estimates of the levels of PPRS payments expected in 2014/15 and 2015/16 when the payment percentage for 2015 was published in December 2014 at: <a href="https://www.gov.uk/government/publications/pprs-payment-percentage" target="_blank">https://www.gov.uk/government/publications/pprs-payment-percentage</a></p><br /><p>The Department intends to publish updated estimates for 2014/15, 2015/16 and 2016/17 in December 2015 when the payment percentage for 2016 is announced. The Department is not able to provide estimates for later years of the scheme as they would be very misleading due to the uncertainty involved.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13351 question first answered 02/11/2015 10:42:13 answering member 4020 label Biography information for George Freeman attachment 1 file name Total quarterly PPRS income- Scotland, N Ireland & Wales Q1 2014-Q2 2015.docx title Quarterly PPRS income- Scotland, N Ireland, Wales
tabling member	18 label Biography information for Dame Cheryl Gillan